Effectiveness of antismoking drug treatment in patients with psychiatric comorbidity compared with patients without this comorbidity.
There is a relationship between smoking and some psychiatric disorders, and there is doubt whether antismoking treatment will be more complex because of psychiatric disorder. To analyze the differences in treatment success rates among patients without psychiatric disorder and patients with psychiatric disorder who have received complete pharmacological treatment. A retrospective cohort study was conducted using the records of patients completely treated at Albacete University Hospital Complex during 2011. The sample comprised 293 patients seen in 2011. We treated only 73 patients and divided them into patients with or without psychiatric disorders. We analyzed the following variables: sex, age, age at smoking onset, previous quitting attempts, cigarettes per day, CO-oximetry, Fagerström test, Richmond test, alcoholism, treatment distribution, treatment failure, success, and relapse. Of a total sample of 293 patients seen in 2011, 73 patients were treated: 43 were men and 30 were women. Overall, 37% had psychiatric disorder (five men and 22 women). Treatment was successful in 51 (70%) patients. There were no differences between the demographic characteristics of the two groups, except for sex (P<0.05); or regarding success, failure, or relapse; or regarding success analyzed separately according to sex distribution. Smoking cessation treatment is equally effective in patients with and without psychiatric disorders. The characteristics of the patients with psychiatric disorders who completed the pharmacological treatment did not differ in intensity, motivation, or dependence from those with no psychiatric comorbidity. Smoking women have more psychiatric morbidity; however, the treatment is effective.